中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Issue 12
Dec.  2018
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2018  >  34(12): 2515-2519

Epidemiology characteristics of nonalcoholic fatty liver disease in Asia

DOI: 10.3969/j.issn.1001-5256.2018.12.006
Research funding:

 

  • Published Date: 2018-12-20
    Abstract
  • The prevalence rate of nonalcoholic fatty liver disease (NAFLD) is constantly increasing due to the increase in the degree of industrialization in Asian countries and the change in lifestyle and dietary structure. Asia has a large population with uneven distribution and marked regional disparities in economic and education levels and lifestyle, which results in the great difference in the epidemiology of NAFLD across different regions in Asia. An understanding of epidemiological features of NAFLD, including incidence, prevalence, and mortality rates and related risk factors can provide a basis for the research on disease progression and related prevention and control strategies.

     

    • FullText(HTML)
    • References(34)
  • [1] NOUREDDIN M, VIPANI A, BRESEE C, et al. NASH leading cause of liver transplant in women:Updated analysis of indications for liver transplant and ethnic and gender variances[J]. Am J Gastroenterol, 2018.[Epub ahead of print]
    [2] CHITTURI S, FARRELL GC, HASHIMOTO E, et al. Non-alcoholic fatty liver disease in the Asia-Pacific region:Definitions and overview of proposed guidelines[J]. J Gastroenterol Hepatol, 2007, 22 (6) :778-787.
    [3] WONG VW, CHAN WK, CHITTURI S, et al. Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines2017-Part 1:Definition, risk factors and assessment[J]. J Gastroenterol Hepatol, 2018, 33 (1) :70-85.
    [4] YOUNOSSI ZM, KOENIG AB, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64 (1) :73-84.
    [5] SETO WK, YUEN MF. Nonalcoholic fatty liver disease in Asia:Emerging perspectives[J]. J Gastroenterol, 2017, 52 (2) :164-174.
    [6] PERUMPAIL BJ, KHAN MA, YOO ER, et al. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease[J].World J Gastroenterol, 2017, 23 (47) :8263-8276.
    [7] FARRELL GC, WONG VW, CHITTURI S. NAFLD in Asia-as common and important as in the West[J]. Nat Rev Gastroenterol Hepatol, 2013, 10 (5) :307-318.
    [8] SINGH S, KUFTINEC GN, SARKAR S. Non-alcoholic fatty liver disease in South Asians:A review of the literature[J]. J Clin Transl Hepatol, 2017, 5 (1) :76-81.
    [9] PATI GK, SINGH SP. Nonalcoholic fatty liver disease in South Asia[J]. Euroasian J Hepatogastroenterol, 2016, 6 (2) :154-162.
    [10] KARIMI-SARI H, MOUSAVI-NAEINI SM, KHONCHE A.Comments on prevalence of non-alcoholic fatty liver disease and its related factors in Iran[J]. Int J Organ Transplant Med, 2017, 8 (1) :52-53.
    [11] GOH SC, HO ELM, GOH KL. Prevalence and risk factors of nonalcoholic fatty liver disease in a multiracial suburban Asian population in Malaysia[J]. Hepatol Int, 2013, 7 (2) :548-554.
    [12] JIE L, BIYAO Z, HIDEKI F, et al. Prevalence of non-alcoholic fatty liver disease (NAFLD) in Asia:A systematic review and meta-analysisof 195 studies and 1, 753, 168 subjects from 13 countries[C]. The 27th Asian Pacific Association for the Study of the Liver, 2018.
    [13] FAN JG, KIM SU, WONG VW. New trends on obesity and NAFLD in Asia[J]. J Hepatol, 2017, 67 (4) :862-873.
    [14] VANWAGNER LB, ARMSTRONG MJ. Lean NAFLD:A not so benign condition?[J]. Hepatol Commun, 2018, 2 (1) :5-8.
    [15] FUNG J, LEE CK, CHAN M, et al. High prevalence of non-alcoholic fatty liver disease in the Chinese-results from the Hong Kong liver health census[J]. Liver Int, 2015, 35 (2) :542-549.
    [16] LI Z, XUE J, CHEN P, et al. Prevalence of nonalcoholic fatty liver disease in mainland of China:A meta-analysis of published studies[J]. J Gastroenterol Hepatol, 2014, 29 (1) :42-51.
    [17] ESTES C, ANSTEE QM, TERESA ARIAS-LOSTE M, et al.Modeling NAFLD disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030[J]. J Hepatol, 2018, 69 (4) :896-904.
    [18] YOUNOSSI Z, TACKE F, ARRESE M, et al. Global perspectives on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis[J]. Hepatology, 2018.[Epub ahead of print]
    [19] FAZEL Y, KOENIG AB, SAYINER M, et al. Epidemiology and natural history of non-alcoholic fatty liver disease[J]. Metabolism, 2016, 65 (8) :1017-1025.
    [20] NIRIELLA MA, PATHMESWARAN A, DE SILVA ST, et al. Incidence and risk factors for non-alcoholic fatty liver disease:A 7-year follow-up study among urban, adult Sri Lankans[J]. Liver Int, 2017, 37 (11) :1715-1722.
    [21] ZHANG T, ZHANG C, ZHANG Y, et al. Metabolic syndrome and its components as predictors of nonalcoholic fatty liver disease in a northern urban Han Chinese population:A prospective cohort study[J]. Atherosclerosis, 2015, 240 (1) :144-148.
    [22] WU J, HE S, XU H, et al. Non-alcoholic fatty liver disease incidence, remission and risk factors among a general Chinese population with a 6-year follow-up[J]. Sci Rep, 2018, 8 (1) :7557.
    [23] DICKSON I. NAFLD:Increased familial risk of fibrosis in NAFLD[J].Nat Rev Gastroenterol Hepatol, 2017, 14 (8) :450.
    [24] NAKAHARA T, HYOGO H, YONEDA M, et al. Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients[J]. J Gastroenterol, 2014, 49 (11) :1477-1484.
    [25] MIYAKE T, KUMAGI T, HIROOKA M, et al. Significance of exercise in nonalcoholic fatty liver disease in men:A communitybased large cross-sectional study[J]. J Gastroenterol, 2015, 50 (2) :230-237.
    [26] TAO Y, GU H, WU J, et al. Thyroid function is associated with non-alcoholic fatty liver disease in euthyroid subjects[J]. Endocr Res, 2015, 40 (2) :74-78.
    [27] SHEN J, WONG GL, CHAN HL, et al. PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome[J]. Aliment Pharmacol Ther, 2014, 39 (5) :532-539.
    [28] FRACANZANI AL, PETTA S, LOMBARDI R, et al. Liver and cardiovascular damage in patients with lean nonalcoholic fatty liver disease, and association with visceral obesity[J]. Clin Gastroenterol Hepatol, 2017, 15 (10) :1604-1611, e1601.
    [29] MASARONE M, FEDERICO A, ABENAVOLI L, et al. Non alcoholic fatty liver:Epidemiology and natural history[J]. Rev Recent Clin Trials, 2014, 9 (3) :126-133.
    [30] MARCUCCILLI M, CHONCHOL M. NAFLD and chronic kidney disease[J]. Int J Mol Sci, 2016, 17 (4) :562.
    [31] SINN DH, KANG D, JANG HR, et al. Development of chronic kidney disease in patients with non-alcoholic fatty liver disease:A cohort study[J]. J Hepatol, 2017, 67 (6) :1274-1280.
    [32] LEE DY, PARK JK, HUR KY, et al. Association between nonalcoholic fatty liver disease and bone mineral density in postmenopausal women[J]. Climacteric, 2018, 21 (5) :498-501.
    [33] SHEN F, ZHENG RD, SHI JP, et al. Impact of skin capsular distance on the performance of controlled attenuation parameter in patients with chronic liver disease[J]. Liver Int, 2015, 35 (11) :2392-2400.
    [34] FLORES A, MARRERO JA. Emerging trends in hepatocellular carcinoma:Focus on diagnosis and therapeutics[J]. Clin Med Insights Oncol, 2014, 8:71-76.
    • Relative Articles

  • Relative Articles

    [1]Aiping TIAN, Yongfeng YANG. Diagnosis of nonalcoholic fatty liver disease: The importance of pathology[J]. Journal of Clinical Hepatology, 2023, 39(3): 491-497. doi: 10.3969/j.issn.1001-5256.2023.03.002
    [2]Rui HAN, Liaoyun ZHANG. Clinical epidemiology and pathological features of cryptogenic cirrhosis[J]. Journal of Clinical Hepatology, 2022, 38(7): 1650-1653. doi: 10.3969/j.issn.1001-5256.2022.07.036
    [3]Shan SHAN, Lianhui ZHAO, Hong MA, Xiaojuan OU, Hong YOU, Jidong JIA. Definition, etiology, and epidemiology of liver cirrhosis[J]. Journal of Clinical Hepatology, 2021, 37(1): 14-16. doi: 10.3969/j.issn.1001-5256.2021.01.003
    [4]YU Di, YANG XuYao, ZHAO JinHan, CHUAN LiXue, CHANG Jiang. Association between anxiety and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(11): 2589-2592. doi: 10.3969/j.issn.1001-5256.2020.11.043
    [5]WANG Xin, HU YiYang, LIU Ping, FENG Qin. Association between hypertension and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(11): 2584-2588. doi: 10.3969/j.issn.1001-5256.2020.11.042
    [6]Yang XuYao, Yu Di, Zhao JinHan, Chuan LiXue, Chang Jiang. Association between nonalcoholic fatty liver disease and depression[J]. Journal of Clinical Hepatology, 2020, 36(1): 201-204. doi: 10.3969/j.issn.1001-5256.2020.01.048
    [7]Ceng Jing, Fan JianGao. Clinical significance of renaming nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(6): 1205-1207. doi: 10.3969/j.issn.1001-5256.2020.06.002
    [8]Yao ChengZi, Feng Gong, Yu WenSi, Du Huan, Mi Man. Risk factors for the development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(2): 433-436. doi: 10.3969/j.issn.1001-5256.2020.02.044
    [9]Li Jing, Wang YuFang. Epidemiological features of inflammatory bowel disease with hepatobiliary and pancreatic diseases[J]. Journal of Clinical Hepatology, 2020, 36(7): 1461-1466. doi: 10.3969/j.issn.1001-5256.2020.07.005
    [10]Jiang YuZi, Nie HongMing, Wang Rong. Research advances in the pathogenesis of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2019, 35(11): 2588-2591. doi: 10.3969/j.issn.1001-5256.2019.11.044
    [11]Gong Hang, Li LiangPing. Noninvasive diagnosis of progressive nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2019, 35(2): 406-410. doi: 10.3969/j.issn.1001-5256.2019.02.038
    [12]Chu PeiLing, Wang Qi, Guo XiaoQing, Liu JinChun. Association between chemokines and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2019, 35(7): 1626-1628. doi: 10.3969/j.issn.1001-5256.2019.07.044
    [13]Hu JiangFeng, Lu LunGen. Research advances in the epidemiological features, pathogenesis, and diagnosis and treatment of alcoholic pancreatitis[J]. Journal of Clinical Hepatology, 2019, 35(2): 448-450. doi: 10.3969/j.issn.1001-5256.2019.02.047
    [14]Shu YunRan, Li JunQi, Liu Qiong. Epidemiology of nonalcoholic fatty liver disease and related risk factors[J]. Journal of Clinical Hepatology, 2019, 35(9): 2085-2090. doi: 10.3969/j.issn.1001-5256.2019.09.045
    [15]Suo YuHong, Liu JinChun. Research advances in the treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2018, 34(10): 2232-2236. doi: 10.3969/j.issn.1001-5256.2018.10.038
    [16]Xie Xiao, Lu LunGen. Potential therapeies for nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2017, 33(12): 2439-2443. doi: 10.3969/j.issn.1001-5256.2017.12.042
    [17]Feng Gong, Niu ChunYan. Advances in the treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2017, 33(12): 2433-2438. doi: 10.3969/j.issn.1001-5256.2017.12.041
    [18]Ding YuPing, Li Hai, Zhang Wen, Xia ShiHai, Bi Xun. Epidemiological characteristics of nonalcoholic fatty liver disease with elevated alanine aminotransferase and related risk factors[J]. Journal of Clinical Hepatology, 2017, 33(12): 2355-2360. doi: 10.3969/j.issn.1001-5256.2017.12.020
    [19]Wang LiFeng, Li YuanYuan, Jin Lei, Wang FuSheng. Epidemiology and natural history of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(2): 165-170. doi: 10.3969/j.issn.1001-5256.2015.02.005
    [20]Fan Xue, Jia JiDong. Diagnosis and treatment of primary biliary cirrhosis in Pacific Asia region[J]. Journal of Clinical Hepatology, 2010, 26(4): 365-367.
    • Supplements(0)
    • Cited By

  • Cited by

    Periodical cited type(33)

    1. 喻晓凡，惠登城，孙明瑜. 柴胡皂苷D调控AMPK和NF-κB通路改善NAFLD的机制研究. 时珍国医国药. 2025(01): 25-33 .
    2. 王颖捷，程昊然，周卫红. 体脂成分及代谢指标与非肥胖人群代谢相关脂肪性肝病的相关性研究. 中国全科医学. 2023(06): 672-680 .
    3. 庞力，金伟. 八段锦对非酒精性脂肪肝患者临床观察. 光明中医. 2023(04): 673-676 .
    4. 陈慧慧，王乾皓，陈润花，王允亮，张烨，焦瑶，袁亚利，谢春娥. 中药代茶饮干预非酒精性脂肪性肝病湿热蕴结证的临床研究. 中华中医药杂志. 2023(02): 902-905 .
    5. 梁君红，李东霞. 非酒精性脂肪性肝病与心律失常相关性的研究进展. 岭南心血管病杂志. 2023(01): 106-110 .
    6. 杨琦，陈晓雯. 基于“玄府-伏毒-肝络”理论论治非酒精性脂肪性肝病. 中西医结合肝病杂志. 2023(05): 442-443 .
    7. 周庆锋. 广西某地区机关单位体检人员脂肪肝与高血压、血脂异常、高尿酸血症的相关性分析. 大众科技. 2023(04): 185-188+184 .
    8. 惠登城，王铮，边艳琴，孙明瑜. 孙明瑜教授运用一气周流理论治疗NAFLD用药规律探讨. 光明中医. 2023(18): 3538-3541 .
    9. 冯丽辉，万雪峰，郑忠蕊，韩海瑞，范明明. 柴苓术芍饮对肝郁脾虚型非酒精性脂肪性肝病大鼠肝组织氧化应激及炎症因子的影响. 中国中医药科技. 2022(03): 360-363 .
    10. 孙玉莉，孙建光，张永，王伟芹，高占华，阎小燕. 尹常健分期辨治非酒精性脂肪性肝病经验. 山东中医杂志. 2022(05): 465-469 .
    11. 陈盈，高雪玲，吴英俊，袁晓环，李鲁新. 姜黄素类似物(H8)改善非酒精性脂肪性肝病的炎症反应及作用机制. 牡丹江医学院学报. 2022(04): 29-34 .
    12. 李琳，何妍，王爽，檀丽冰，秦雪英，李全民，白玉蓉. 脂肪肝指数对2型糖尿病发病风险预测作用的队列研究. 中华糖尿病杂志. 2022(09): 934-939 .
    13. 林军，苏林红，叶小丹，朱小区. 基于“脾虚浊凝”理论探讨非酒精性脂肪性肝病辨治思路. 浙江中医药大学学报. 2022(10): 1156-1160 .
    14. 李莎，寇少杰，薛敬东. 薛敬东运用“浊毒理论”治疗非酒精性脂肪肝经验总结. 陕西中医. 2021(03): 363-365 .
    15. 李韵晴，莫娇，郑志坚，陈慕婷，张宁，王新航，唐深，陆彩玲，李习艺. 苯并(a)芘调节脂代谢促进Hep G2细胞脂质沉积. 现代预防医学. 2021(07): 1281-1285 .
    16. 叶小丹，陈剑，朱小区. 保肝降脂方联合水飞蓟宾治疗湿浊内停型代谢相关脂肪性肝病临床研究. 新中医. 2021(09): 43-46 .
    17. 梁涵子，李雨涵，李家瑞，李建宁，宋辉，杨怡. 棕榈酸联合TGF-β1诱导脂肪性肝纤维化细胞模型. 宁夏医科大学学报. 2021(06): 549-555 .
    18. 徐异彩，张冉，王小颖，杨春燕，武云哲. 超声E成像在非酒精性脂肪性肝病中的诊断价值研究. 现代生物医学进展. 2021(18): 3482-3485 .
    19. 曹林，李茜，纪龙珊，高月求，李曼. 中性粒细胞胞外诱捕网的形成机制及在肝病中的作用. 临床肝胆病杂志. 2020(01): 205-207 . 本站查看
    20. 陆孝良，蒋元烨，曹勤. 氧化应激与核因子E2相关因子2在非酒精性脂肪性肝病中的作用. 临床肝胆病杂志. 2020(04): 924-927 . 本站查看
    21. 黄海燕，韦荣新，何广营，曾辉苑. 深圳市出租车司机与机关事业单位人员非酒精性脂肪肝患病率比较及影响因素分析. 中西医结合肝病杂志. 2020(02): 166-168 .
    22. 王向红，马葆华，邹秀兰，姚克铖，贺茜. 非酒精性脂肪性肝病与心外膜脂肪组织关系的Meta分析. 临床肝胆病杂志. 2020(06): 1304-1309 . 本站查看
    23. 胡峦，李艳，钟伟传，李镇武. 非酒精性脂肪性肝病患者血清维生素D水平及其受体基因Bsm I位点多态性分析. 中西医结合肝病杂志. 2020(03): 215-217+241 .
    24. 高静静，汪涛，蒋元烨，曹勤. 非酒精性脂肪性肝病代谢组学与中医证候. 临床肝胆病杂志. 2020(08): 1880-1882 . 本站查看
    25. 芮法娟，杨红丽，吕卓珍，郭朝阳，任万华，秦成勇，李晓梅，李婕. 非酒精性脂肪性肝病的流行病学研究进展. 山东医药. 2020(31): 89-92 .
    26. 何聪，孔婧，王慧超，唐义爽，王晓素. 祛湿化瘀法治疗非酒精性脂肪肝研究进展. 陕西中医. 2020(12): 1843-1845 .
    27. 常越，张文，刘沁雨，张青，陈凯，李海. 水飞蓟宾治疗对非酒精性脂肪性肝病患者转氨酶影响的Meta分析. 临床肝胆病杂志. 2019(05): 1057-1060 . 本站查看
    28. 简玲丽，杨烨. 益生菌对非酒精性脂肪性肝病的疗效及T淋巴细胞亚群的影响. 中国现代医生. 2019(17): 1-3 .
    29. 王晓晓，赵洁，李晓鹤，饶慧瑛，魏来，刘峰. 二次谐波/双光子激发荧光显微成像技术定量评估非酒精性脂肪性肝病小鼠模型肝纤维化的价值. 临床肝胆病杂志. 2019(08): 1786-1790 . 本站查看
    30. 王欣，胡义扬，冯琴. 脂肪性肝纤维化小鼠模型研究现状. 临床肝胆病杂志. 2019(08): 1865-1869 . 本站查看
    31. 谭丽萍，石安华，朱晓松，邓雪，李继晓，陈文慧. 基于自噬探讨中药复方治疗非酒精性脂肪性肝病作用机制的研究进展. 中国医药导报. 2019(34): 50-53 .
    32. 韩晶，孟繁坤，胡星. 轻度乙型肝炎合并非酒精性脂肪性肝病与单纯非酒精性脂肪性肝病患者皮下脂肪厚度、肝功能及血脂的差异. 中国肝脏病杂志(电子版). 2019(04): 67-72 .
    33. 梅婷婷，汤珊，张晶，于海滨. 跨膜6超家族成员2 E167K基因多态性与肝脏疾病相关性研究进展. 国际病毒学杂志. 2019(05): 351-354 .

    Other cited types(31)

  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 5.9 %FULLTEXT: 5.9 %META: 80.7 %META: 80.7 %PDF: 13.4 %PDF: 13.4 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 5.7 %其他: 5.7 %其他: 1.4 %其他: 1.4 %China: 0.5 %China: 0.5 %India: 0.2 %India: 0.2 %Russian Federation: 0.2 %Russian Federation: 0.2 %San Lorenzo: 0.2 %San Lorenzo: 0.2 %[]: 0.2 %[]: 0.2 %上海: 3.0 %上海: 3.0 %中山: 0.2 %中山: 0.2 %佛山: 0.2 %佛山: 0.2 %北京: 5.4 %北京: 5.4 %南宁: 0.2 %南宁: 0.2 %南昌: 0.5 %南昌: 0.5 %吉林: 5.3 %吉林: 5.3 %天津: 0.2 %天津: 0.2 %巴塞罗那: 0.2 %巴塞罗那: 0.2 %广州: 1.3 %广州: 1.3 %弗吉: 0.3 %弗吉: 0.3 %张家口: 1.6 %张家口: 1.6 %德罕: 0.3 %德罕: 0.3 %惠州: 0.3 %惠州: 0.3 %成都: 0.5 %成都: 0.5 %扬州: 0.3 %扬州: 0.3 %昆明: 0.5 %昆明: 0.5 %杭州: 1.9 %杭州: 1.9 %武汉: 0.6 %武汉: 0.6 %泰安: 0.6 %泰安: 0.6 %洛阳: 0.2 %洛阳: 0.2 %济南: 0.8 %济南: 0.8 %深圳: 0.5 %深圳: 0.5 %瑟普赖斯: 0.2 %瑟普赖斯: 0.2 %福州: 0.6 %福州: 0.6 %芒廷维尤: 33.5 %芒廷维尤: 33.5 %苏州: 0.5 %苏州: 0.5 %莫斯科: 2.4 %莫斯科: 2.4 %西宁: 22.6 %西宁: 22.6 %西安: 0.5 %西安: 0.5 %诺沃克: 0.2 %诺沃克: 0.2 %运城: 0.2 %运城: 0.2 %郑州: 1.1 %郑州: 1.1 %重庆: 0.5 %重庆: 0.5 %长春: 2.1 %长春: 2.1 %长沙: 0.8 %长沙: 0.8 %长治: 0.8 %长治: 0.8 %阳江: 0.6 %阳江: 0.6 %青岛: 0.2 %青岛: 0.2 %香港特别行政区: 0.3 %香港特别行政区: 0.3 %其他其他ChinaIndiaRussian FederationSan Lorenzo[]上海中山佛山北京南宁南昌吉林天津巴塞罗那广州弗吉张家口德罕惠州成都扬州昆明杭州武汉泰安洛阳济南深圳瑟普赖斯福州芒廷维尤苏州莫斯科西宁西安诺沃克运城郑州重庆长春长沙长治阳江青岛香港特别行政区

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1832) PDF downloads(482) Cited by(64)
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[2034]YesterdayPV[4003]TodayIP[2045]TodayPV[4018]Online[72]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return